Beyond HIV microbicides: Multipurpose prevention technology products

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 121, Issue s5, 2014, Pages 62-69

  Malcolm, R K ^a   Boyd, P ^a   McCoy, C F ^a   Murphy, D J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

combination products; contraception; microbicide; MPTs

Indexed keywords

ASTODRIMER; CARRAGEENAN; CONTRACEPTIVE AGENT; DAPIVIRINE; ETONOGESTREL; MARAVIROC; MEDROXYPROGESTERONE ACETATE; MICROBICIDE; N [3 [4 (3 BENZYL 1 ETHYL 5 PYRAZOLYL) 1 PIPERIDINYLMETHYL] 4 (3 FLUOROPHENYL)CYCLOPENTYL] N METHYLVALINE; PRO 2000; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPERMICIDAL AGENT; VACCINE; DRUG COMBINATION;

BARRIER CONTRACEPTION; CLINICAL EFFECTIVENESS; CONDOM; DRUG FORMULATION; DRUG IMPLANT; FEMALE CONDOM; GENE THERAPY; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAUTERINE CONTRACEPTIVE DEVICE; REPRODUCTIVE HEALTH; REVIEW; SEXUALLY TRANSMITTED DISEASE; TRANSDERMAL PATCH; UNPLANNED PREGNANCY; UTERINE CERVIX CAP; VAGINA RING; CONTRACEPTIVE DEVICE; DRUG COMBINATION; FEMALE; HIV INFECTIONS; PREGNANCY; SEXUALLY TRANSMITTED DISEASES; WOMEN'S HEALTH;

CONTRACEPTIVE DEVICES; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; PREGNANCY; PREGNANCY, UNPLANNED; REPRODUCTIVE HEALTH; SEXUALLY TRANSMITTED DISEASES; WOMEN'S HEALTH;

EID: 84916214797     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.12852     Document Type: Review

References (58)

1. Abdool Karim Q, Abdool Karim S, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74.
2. Friend DR, Doncel GF,. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: development of dual-protection technologies. Antiviral Res 2010; 88: S47-54.
3. Friend DR,. Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections. Drug Delivery Trans Res 2011; 1: 185-93.
4. Friend DR,. Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission. Expert Opin Drug Deliv 2012; 9: 417-27.
5. Harrison PF, Hemmerling A, Romano J, Whaley KJ, Young Holt B,. Developing multipurpose reproductive health technologies: an integrated strategy. AIDS Res Treat 2013; 00: 790154.
6. Holt BY, Kilbourne-Brook M, Stone A, Harrison P, Shields WC,. Multipurpose prevention technologies for sexual and reproductive health: gaining momentum and promise. Contraception 2010; 81: 177-80.
7. Malcolm RK, Fetherston SM,. Delivering on MPTs: addressing the needs, rising to the challenges and making the opportunities. Contraception 2013; 88: 321-5.
8. Thurman AR, Clark MR, Doncel GF,. Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol 2011; 2011: 1-10.
9. Thurman AR, Doncel GF,. Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention. Int J STD AIDS 2012; 23: 613-9.
10. Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR,. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res 2010; 88: S55-6.
11. Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, van den Oord J, et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 2011; 10: 379-89.
12. Ball C, Krogstad E, Chaowanachan T, Woodrow KA,. Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS ONE 2012; 7: e49792.
13. Major I, Boyd P, Kilbourne-Brook M, Saxon G, Cohen J, Malcolm RK,. A modified SILCS contraceptive diaphragm for long-term controlled release of the HIV microbicide dapivirine. Contraception 2013; 88: 58-66.
14. Mesquita PM, Rastogi R, Segarra TJ, Teller RS, Torres NM, Huber AM, et al. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother 2012; 67: 1730-8.
15. Moss JA, Malone AM, Smith TJ, Kennedy S, Nguyen C, Vincent KL, et al. Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model. Antimicrob Agents Chemother 2013; 57: 3994-7.
16. Podolsky SH, Greene JA,. Combination drugs-hype, harm, and hope. N Engl J Med 2011; 365: 488-91.
17. Lodola A,. Developing combination drugs in preclinical studies. In:, Jean-Charles G, editor. Drug Safety Evaluation: Methods and Protocols, Methods in Molecular Biology, vol. 691. Berlin: Springer; 2009. pp. 3-16.
18. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH,. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-9.
19. Pan F, Chernew ME, Fendrick AM,. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008; 23: 611-4.
20. Wertheimer AI,. The economics of polypharmacology: fixed dose combinations and drug cocktails. Curr Med Chem 2013; 20: 1635-8.
21. CAMI Health, Multipurpose Prevention Technologies for Reproductive Health: Product Prioritization Stakeholder Meeting, 2012. [ www.cami-health.org/documents/2012SAWG-Report-FinalReport.pdf ]. Accessed 13 May 2014.
22. Vibholm L, Reinert LS, Søgaard OS, Paludan SR, Østergaard L, Tolstrup M, et al. Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection. AIDS Res Hum Retroviruses 2012; 28: 1404-11.
23. Fetherston SM, Boyd P, McCoy CF, McBride MC, Edwards KL, Ampofo S, et al. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. Eur J Pharm Sci 2012; 48: 406-15.
24. Forbes CJ, Lowry D, Geer L, Veazey RS, Shattock RJ, Klasse PJ, et al. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release 2011; 156: 161-9.
25. Malcolm RK, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ,. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother 2012; 56: 2251-8.
26. Malcolm RK, Forbes CJ, Geer L, Veazey RS, Goldman L, Klasse PJ, et al. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother 2013; 68: 678-83.
27. Terrazas-Aranda K, Van Herrewege Y, Hazuda D, Lewi P, Costi R, Di Santo R, et al. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob Agents Chemother 2008; 52: 2544-54.
28. Herrera C, Shattock RJ,. Potential use of protease inhibitors as vaginal and colorectal microbicides. Curr HIV Res 2012; 10: 42-52.
29. Dereuddre-Bosquet N, Morellato-Castillo L, Brouwers J, Augustijns P, Bouchemal K, Ponchel G, et al. MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV162P3 in cynomolgus macaques. PLoS Pathog 2012; 8: e10030.
30. Recum HA, Pokorski JK,. Peptide and protein-based inhibitors of HIV-1 co-receptors. Exp Biol Med 2013; 238: 442-9.
31. Vanpouille C, Arakelyan A, Margolis L,. Microbicides: still a long road to success. Trends Microbiol 2012; 20: 369-75.
32. Rupp R, Rosenthal SL, Stanberry LR,. VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine 2007; 2007: 561-6.
33. ®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS ONE 2011; 6: e24095.
34. Frezieres RG, Walsh T, Kilbourne-Brook M, Coffey PS,. Couples' acceptability of the SILCS diaphragm for microbicide delivery. Contraception 2012; 85: 99-107.
35. Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP,. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci USA 2012; 109: 8694-8.
36. Morrow RJ, Woolfson AD, Donnelly L, Curran R, Andrews G, Katinger D, et al. Sustained release of proteins from a modified vaginal ring device. Eur J Pharm Biopharm 2011; 77: 3-10.
37. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. New Engl J Med 2012; 366: 1998-2007.
38. Mansour D, Inki P, Gemzell-Danielsson K,. Efficacy of contraceptive methods: a review of the literature. Eur J Contracept Reprod Health Care 2010; 15: 4-16.
39. Ferrer RA, Morrow KM, Fisher WA, Fisher JD,. Toward an information-motivation-behavioral skills model of microbicide adherence in clinical trials. AIDS Care 2010; 22: 997-1005.
40. Tolley EE, Harrison PF, Goetghebeur E, Morrow K, Pool R, Taylor D, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav 2010; 14: 1124-36.
41. Kiser PF, Johnson TJ, Clark JT,. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev 2012; 14: 62-77.
42. Malcolm RK, Fetherston SM, McCoy CF, Boyd P, Major I,. Vaginal rings for delivery of HIV microbicides. Int J Women's Health 2012; 4: 595-605.
43. Friend DR, Kiser PF,. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antiviral Res 2013; 99: 391-400.
44. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD,. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 2005; 56: 954-6.
45. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD,. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 2006; 325: 82-9.
46. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009; 51: 416-23.
47. Gilliam M, Holmquist S, Berlin A,. Factors associated with willingness to use the contraceptive vaginal ring. Contraception 2007; 76: 30-4.
48. Hardy E, Hebling EM, Sousa MH, Almeida AF, Amaral E,. Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences. Contraception 2007; 76: 126-31.
49. Weisberg E, Fraser IS, Lacarra M, Mishell DR, Jackanicz T,. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring. Contraception 1997; 56: 233-9.
50. Montgomery ET, van der Straten A, Cheng H, Wegner L, Masenga G, von Mollendorf C, et al. Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav 2012; 16: 1787-98.
51. Szarewski A,. High acceptability and satisfaction with NuvaRing use. Eur J Contracept Reprod Health Care 2002; 7 (Suppl 2): 31-6; discussion 37-9.
52. Stewart FH, Brown BA, Raine TR, Weitz TA, Harper CC,. Adolescent and young women's experience with the vaginal ring and oral contraceptive pills. J Pediatr Adolesc Gynecol 2007; 20: 345-51.
53. Speroff L,. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 2003; 102: 823-34.
54. Roumen FJ, Apter D, Mulders TM, Dieben TO,. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001; 16: 469-75.
55. Dieben TOM, Roumen FJME, Apter D,. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002; 100: 585-93.
56. Roumen FJ, Dieben TO,. Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring. Contraception 1999; 59: 59-62.
57. Buckler H, Al-Azzawi F,. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women. BJOG 2003; 110: 753-9.
58. Johnson TJ, Gupta KM, Fabian J, Albright TH, Kiser PF,. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci 2010; 39: 203-12.